Our study in Scientific Reports evaluates the performance of the CytoBead ANA 2 assay, a novel one-step method for detecting antinuclear antibodies (ANA) and specific autoantibodies in systemic autoimmune rheumatic diseases (SARDs).
We compared CytoBead ANA 2 to traditional ANA indirect immunofluorescence (IIF) and the BioPlex™ 2200 multiplexed assay, finding substantial agreement (κ=0.74) and comparable diagnostic accuracy. The assay also effectively identified the dense-fine speckled (DFS) pattern associated with anti-DFS70 antibodies in non-SARDs patients.
This approach streamlines ANA testing by combining screening and confirmation in a single step, offering a promising alternative to the current two-tier process.
Read the full paper: Nature Scientific Reports
#Autoimmunity #Rheumatology #Diagnostics #ANA #Research